Trial Profile

A prospective open follow-up study with 10 000 mTU/mL mannan-conjugated birch pollen allergoids administered subcutaneously to participants of the T502-SIT-020 trial

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 15 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs T 502 (Primary)
Indications Allergic rhinitis; Allergic rhinoconjunctivitis
Focus Therapeutic Use
Sponsors Inmunotek

Most Recent Events

31 Jul 2023 Status changed from recruiting to completed.
10 Apr 2023 Trial design and clinical development of T502 from three clinical studies presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
28 Dec 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com